{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:59:12Z","timestamp":1776214752972,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To describe patients\u2019 use of opioids in the year preceding and year following new diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), compared with patients without the\/se diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study used US IBM<jats:sup>\u00ae<\/jats:sup> MarketScan<jats:sup>\u00ae<\/jats:sup> Commercial Claims and Encounters (CCAE) and Medicaid data and included three cohorts, comprised of incident cases of AS, PsA, or RA (2010\u20132017). Three matched comparator patients (without the incident disease) were selected for each patient within the disease cohort. Opioid use and appropriate treatment exposure (as defined by US guideline recommendations) in the 12-month baseline and follow-up periods were evaluated using descriptive analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Prevalence of claims for opioids was higher for disease cohorts vs. comparators in CCAE; 36.4% of patients with AS, 29.5% with PsA, and 44.4% with RA did not have any claim for guideline-appropriate therapy in follow-up. Prevalence of claims for opioids was also higher for disease cohorts vs. comparators in Medicaid; 30.6% of patients with AS, 36.6% with PsA, and 65.4% with RA did not have any claim for guideline-appropriate therapy in follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with AS, PsA, or RA, there was high reliance on opioids at and around the time of diagnosis. Significant proportions of patients were not on appropriate treatment as defined by professional society post-diagnosis guidelines; this discordance between actual patient therapies and treatment recommendations may suggest a need for better awareness of appropriate pain management and treatment strategies in rheumatic diseases.<\/jats:p>\n                <jats:p><jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\"><jats:bold>Key Points<\/jats:bold><\/jats:td>\n                      <\/jats:tr>\n                      <jats:tr>\n                        <jats:td align=\"left\">\u2022 <jats:italic>This study analysed opioid use among patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), and adds to current knowledge by expanding beyond assessment of opioid use at diagnosis, to the year before and after diagnosis<\/jats:italic>.\u2022 <jats:italic>Opioid use was found to be highly prevalent in AS, PsA, and RA in the year prior to diagnosis and, interestingly, was still seen during the year after diagnosis<\/jats:italic>.\u2022 <jats:italic>Opioids are neither disease modifying, nor a targeted\/recommended treatment for chronic autoimmune diseases. In addition to their association with significant economic costs, opioids are potentially hazardous and are not better than alternative treatments with superior safety profiles<\/jats:italic>.\u2022 <jats:italic>The reasons behind opioid prescribing patterns should be explored further to support movement to targeted therapies<\/jats:italic>.<\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-024-06945-0","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T02:01:36Z","timestamp":1714010496000},"page":"1897-1907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases"],"prefix":"10.1007","volume":"43","author":[{"given":"Anna","family":"Sheahan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Anjohrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Suruki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-2727","authenticated-orcid":false,"given":"Jeffrey L.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor S.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"6945_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","volume":"7","author":"W Zhu","year":"2019","unstructured":"Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Qiu G et al (2019) Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res 7:22. https:\/\/doi.org\/10.1038\/s41413-019-0057-8","journal-title":"Bone Res"},{"key":"6945_CR2","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167\u20132172","journal-title":"J Rheumatol"},{"key":"6945_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrrheum.2017.92","volume":"13","author":"K Bidad","year":"2017","unstructured":"Bidad K, Gracey E, Hemington KS, Mapplebeck JCS, Davis KD, Inman RD (2017) Pain in ankylosing spondylitis: a neuro-immune collaboration. Nat Rev Rheumatol 13:410\u2013420. https:\/\/doi.org\/10.1038\/nrrheum.2017.92","journal-title":"Nat Rev Rheumatol"},{"key":"6945_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"6945_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3899\/jrheum.150642","volume":"93","author":"O Addimanda","year":"2015","unstructured":"Addimanda O, Possemato N, Caruso A, Pipitone N, Salvarani C (2015) The Role of Tumor Necrosis Factor-\u03b1 Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis. J Rheumatol 93:73\u201378. https:\/\/doi.org\/10.3899\/jrheum.150642","journal-title":"J Rheumatol"},{"key":"6945_CR6","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, Ward MM et al (2013) The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65:2645\u20132654. https:\/\/doi.org\/10.1002\/art.38070","journal-title":"Arthritis Rheum"},{"key":"6945_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/art.38068","volume":"65","author":"P Machado","year":"2013","unstructured":"Machado P (2013) Anti-tumor necrosis factor and new bone formation in ankylosing spondylitis: the controversy continues. Arthritis Rheum 65:2537\u20132540. https:\/\/doi.org\/10.1002\/art.38068","journal-title":"Arthritis Rheum"},{"key":"6945_CR8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception cohort. Ann Rheum Dis 71:1616\u20131622. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201252","journal-title":"Ann Rheum Dis"},{"key":"6945_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","volume":"165","author":"H Radner","year":"2015","unstructured":"Radner H, Aletaha D (2015) Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr 165:3\u20139. https:\/\/doi.org\/10.1007\/s10354-015-0344-y","journal-title":"Wien Med Wochenschr"},{"key":"6945_CR10","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, Zeidler H et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756\u20131765. https:\/\/doi.org\/10.1002\/art.21054","journal-title":"Arthritis Rheum"},{"key":"6945_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M et al (2019) Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken) 71:2\u201329. https:\/\/doi.org\/10.1002\/acr.23789","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6945_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA et al (2016) American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 68:282\u2013298. https:\/\/doi.org\/10.1002\/art.39298","journal-title":"Arthritis Rheumatol"},{"key":"6945_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 68:1\u201325. https:\/\/doi.org\/10.1002\/acr.22783","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6945_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-med-011817-044739","volume":"69","author":"N Volkow","year":"2018","unstructured":"Volkow N, Benveniste H, McLellan AT (2018) Use and misuse of opioids in chronic pain. Ann Rev Med 69:451\u2013465","journal-title":"Ann Rev Med"},{"key":"6945_CR15","first-page":"S67","volume":"15","author":"L Manchikanti","year":"2012","unstructured":"Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR et al (2012) American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2\u2013guidance. Pain Physician 15:S67-116","journal-title":"Pain Physician"},{"key":"6945_CR16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R (2016) CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016. JAMA 315:1624\u20131645. https:\/\/doi.org\/10.1001\/jama.2016.1464","journal-title":"JAMA"},{"key":"6945_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.07.003","author":"L Kimsey","year":"2018","unstructured":"Kimsey L, Weissman JS, Patel A, Drew A, Koehlmoos T, Sparks JA (2018) Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. Semin Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.003","journal-title":"Semin Arthritis Rheum"},{"key":"6945_CR18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180972","author":"VS Sloan","year":"2019","unstructured":"Sloan VS, Sheahan A, Stark JL, Suruki RY (2019) Opioid Use in patients with Ankylosing Spondylitis is common in the United States: outcomes of a retrospective cohort study. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.180972","journal-title":"J Rheumatol"},{"key":"6945_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/art.40152","volume":"69","author":"JR Curtis","year":"2017","unstructured":"Curtis JR, Xie F, Smith C, Saag KG, Chen L, Beukelman T, Mannion M et al (2017) Changing trends in opioid use among patients with rheumatoid arthritis in the United States. Arthritis Rheumatol 69:1733\u20131740. https:\/\/doi.org\/10.1002\/art.40152","journal-title":"Arthritis Rheumatol"},{"key":"6945_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3899\/jrheum.170630","volume":"45","author":"JD Dau","year":"2018","unstructured":"Dau JD, Lee M, Ward MM, Gensler LS, Brown MA, Learch TJ, Diekman LA et al (2018) Opioid analgesic use in patients with ankylosing spondylitis: an analysis of the prospective study of outcomes in an ankylosing spondylitis cohort. J Rheumatol 45:188\u2013194. https:\/\/doi.org\/10.3899\/jrheum.170630","journal-title":"J Rheumatol"},{"key":"6945_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/BOR.0000000000000602","volume":"31","author":"AL Day","year":"2019","unstructured":"Day AL, Curtis JR (2019) Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices. Curr Opin Rheumatol 31:264\u2013270. https:\/\/doi.org\/10.1097\/BOR.0000000000000602","journal-title":"Curr Opin Rheumatol"},{"key":"6945_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40744-019-0148-4","volume":"6","author":"T Hunter","year":"2019","unstructured":"Hunter T, Schroeder K, Sandoval D, Deodhar A (2019) Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther 6:207\u2013215. https:\/\/doi.org\/10.1007\/s40744-019-0148-4","journal-title":"Rheumatol Ther"},{"key":"6945_CR23","first-page":"A156","volume":"77","author":"P Muilu","year":"2018","unstructured":"Muilu P, Rantalaiho V, Kautiainen H, Virta LJ, Poulakka K (2018) Time-related trends in opioid purchases among patients with early inflammatory arthritides (OP0215). Ann Rheum Dis 77:A156","journal-title":"Ann Rheum Dis"},{"key":"6945_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jval.2020.07.013","volume":"24","author":"E Beaulieu","year":"2021","unstructured":"Beaulieu E, DiGennaro C, Stringfellow E, Connolly A, Hamilton A, Hyder A, Cerd\u00e1 M et al (2021) Economic evaluation in opioid modeling: systematic review. Value Health 24:158\u2013173. https:\/\/doi.org\/10.1016\/j.jval.2020.07.013","journal-title":"Value Health"},{"key":"6945_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7812\/tpp\/15-151","volume":"20","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Harrold LR, Asgari MM, Deodhar A, Salman C, Gelfand JM, Wu JJ et al (2016) Diagnostic prevalence of Ankylosing Spondylitis using computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. Perm J 20:15\u2013151. https:\/\/doi.org\/10.7812\/tpp\/15-151","journal-title":"Perm J"},{"key":"6945_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.msard.2012.06.001","volume":"1","author":"RA Marrie","year":"2012","unstructured":"Marrie RA, Yu BN, Leung S, Elliott L, Warren S, Wolfson C, Tremlett H et al (2012) The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: a population-based study. Mult Scler Relat Disord 1:162\u2013167. https:\/\/doi.org\/10.1016\/j.msard.2012.06.001","journal-title":"Mult Scler Relat Disord"},{"key":"6945_CR27","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s10067-016-3231-z","volume":"35","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Mittal M, Reilly P, Bao Y, Manthena S, Anderson J, Joshi A (2016) Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol 35:1769\u20131776. https:\/\/doi.org\/10.1007\/s10067-016-3231-z","journal-title":"Clin Rheumatol"},{"key":"6945_CR28","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1136\/annrheumdis-2013-204867","volume":"74","author":"J Sorensen","year":"2015","unstructured":"Sorensen J, Hetland ML, all departments of rheumatology in D, (2015) Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74:e12. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204867","journal-title":"Ann Rheum Dis"},{"key":"6945_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/OARRR.S138830","volume":"9","author":"AS Barhamain","year":"2017","unstructured":"Barhamain AS, Magliah RF, Shaheen MH, Munassar SF, Falemban AM, Alshareef MM, Almoallim HM (2017) The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. Open Access Rheumatol 9:139\u2013150. https:\/\/doi.org\/10.2147\/OARRR.S138830","journal-title":"Open Access Rheumatol"},{"key":"6945_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10067-007-0727-6","volume":"27","author":"U Dincer","year":"2008","unstructured":"Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27:457\u2013462. https:\/\/doi.org\/10.1007\/s10067-007-0727-6","journal-title":"Clin Rheumatol"},{"key":"6945_CR31","unstructured":"Medicaid and CHIP Payment and Access Commission. Medicaid and the Opioid Epidemic. 2017:60\u201397, macpac.gov. Accessed: August 11 2021"},{"key":"6945_CR32","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/j.japh.2020.08.002","volume":"60","author":"AN Kokaly","year":"2020","unstructured":"Kokaly AN, Kurlander JE, Pais K, Lee C, Schaefer JK, Heung M, Vordenberg SE (2020) Identification of undocumented over-the-counter medications in an academic nephrology clinic. J Am Pharm Assoc (2003) 60:e236\u2013e245. https:\/\/doi.org\/10.1016\/j.japh.2020.08.002","journal-title":"J Am Pharm Assoc (2003)"},{"key":"6945_CR33","unstructured":"Services USDoHH. Renewal of Determination That A Public Health Emergency Exists. PHE Declarations [serial online]. 2020, HSS.gov. Accessed: 02\/06\/2024"},{"key":"6945_CR34","doi-asserted-by":"publisher","unstructured":"Pazmino S, Boonen A, De Cock D, Stouten V, Joly J, Bertrand D, Westhovens R et al (2021) Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. RMD Open 7. https:\/\/doi.org\/10.1136\/rmdopen-2021-001615","DOI":"10.1136\/rmdopen-2021-001615"},{"key":"6945_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R (2022) CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 71:1\u201395. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1","journal-title":"MMWR Recomm Rep"},{"key":"6945_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.18553\/jmcp.2019.25.1.018","volume":"25","author":"CL Roland","year":"2019","unstructured":"Roland CL, Ye X, Stevens V, Oderda GM (2019) The prevalence and cost of Medicare beneficiaries diagnosed and at risk for opioid abuse, dependence, and poisoning. J Manag Care Spec Pharm 25:18\u201327. https:\/\/doi.org\/10.18553\/jmcp.2019.25.1.018","journal-title":"J Manag Care Spec Pharm"},{"key":"6945_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","volume":"156","author":"KE Vowles","year":"2015","unstructured":"Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN (2015) Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 156:569\u2013576. https:\/\/doi.org\/10.1097\/01.j.pain.0000460357.01998.f1","journal-title":"Pain"},{"key":"6945_CR38","doi-asserted-by":"publisher","unstructured":"Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM (2010) Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev CD006605. https:\/\/doi.org\/10.1002\/14651858.CD006605.pub2","DOI":"10.1002\/14651858.CD006605.pub2"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06945-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:05:10Z","timestamp":1716393910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06945-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6945"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06945-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient data were de-identified; thus, the use of the data does not constitute human subject research and does not require approval from an institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"IBM<sup>\u00ae<\/sup> MarketScan<sup>\u00ae<\/sup> is Health Insurance Portability and Accountability Act (HIPAA) compliant. Patient data were de-identified; thus, the use of the data does not constitute human subject research and does not require approval from an institutional review board. Analyses were performed with permission of the data owner to be presented at an aggregate level.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS: Former employee of UCB Pharma; shareholder of UCB Pharma. SA, JLS: Employees and shareholders of UCB Pharma. RS: Employee of Janssen; former employee of UCB Pharma; shareholder of GSK and UCB Pharma. VSS: Former employee of, consultant to, and shareholder of UCB Pharma; faculty of Rutgers Robert Wood Johnson Medical School; employee of the Peace Corps. This work was prepared by Victor Sloan in his personal capacity. The opinions expressed are not necessarily those of the Peace Corps or the United States government.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}